Skip to main content
SpringerLink
Log in

Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The importance of platelets in coronary artery disease has been better elucidated in the past 20 years with the continued understanding of their role in the development of the atherosclerotic lesion and acute coronary syndromes. The most recent therapeutic efforts have focused on blockade of the platelet glycoprotein IIb/IIIa receptor, which represents the final common pathway to platelet aggregation and arterial thrombus formation. This manuscript summarizes platelet function and pathophysiology, currently available glycoprotein IIb/IIIa inhibitors, and the important clinical trials with this new class of drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332:1553–1559.

    Article  PubMed  CAS  Google Scholar 

  2. Hynes RO: Integrins: a family of cell surface receptors. Cell 1987, 48:549–554.

    Article  PubMed  CAS  Google Scholar 

  3. Frishman WH, Burns B, Atac B, et al.: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995, 130:877–892.

    Article  PubMed  CAS  Google Scholar 

  4. Harker LA, Mann KG: Thrombosis and fibrinolysis. In Cardiovascular Thrombosis, edn 2. Edited by Verstraete M, Fuster V, Topol EJ. Philadelphia: Lippincott-Raven; 1998:3–22.

    Google Scholar 

  5. Gawaz M, Neumann FJ, Schomig A: Evaluation of platelet glycoproteins in coronary artery disease. Circulation 1999:1:e1-e11.

    Google Scholar 

  6. Wencel-Drake JD, Plow EF, Kunicki TJ, et al.: Localization of internal pools of membrane glycoprotein involved in platelet adhesive responses. Am J Pathol 1986, 124:324–334.

    PubMed  CAS  Google Scholar 

  7. Plow EF, Byzova T: The biology of glycoprotein IIb/IIIa. Coron Artery Dis 1999, 10:547–551.

    Article  PubMed  CAS  Google Scholar 

  8. Fujimura K, Phillips DR: Calcium cation regulation of glycoprotein IIb/IIIa complex formation in platelet plasma membranes. J Biol Chem 1983, 258:10247–10252.

    PubMed  CAS  Google Scholar 

  9. Ruoslahti E, Pierschbacher MD: Arg-gly-asp: a versatile cell recognition signal. Cell 1986, 44:517–518.

    Article  PubMed  CAS  Google Scholar 

  10. Plow ER, Marguerie G, Ginsberg M: Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987, 36:4035–4040.

    Article  PubMed  CAS  Google Scholar 

  11. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801–809.

    Article  PubMed  CAS  Google Scholar 

  12. Ross R: Factors influencing atherogenesis. In Hurst’s The Heart, edn 9. Edited by Alexander RW, Schlant RC, Fuster V, et al. New York: McGraw-Hill; 1998:1139–1159.

    Google Scholar 

  13. Badimon L, Badimon JJ, Fuster V: Pathogenesis of thrombosis. In Cardiovascular Thrombosis, edn 2. Edited by Verstraete M, Fuster V, Topol EJ. Philadelphia: Lippincott-Raven; 1998:23–44.

    Google Scholar 

  14. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992, 326:242–250.

    Article  PubMed  CAS  Google Scholar 

  15. Davies MJ: Pathology of coronary atherosclerosis. In Hurst’s The Heart, edn 9. Edited by Alexander RW, Schlant RC, Fuster V, et al. New York: McGraw-Hill; 1998:1161–1174.

    Google Scholar 

  16. Coller BS, Peerschke EI, Scudder LE, Sullivan CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983, 72:325–338.

    Article  PubMed  CAS  Google Scholar 

  17. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibition therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000, 139:S38-S45.

    Article  PubMed  CAS  Google Scholar 

  18. Califf RM: Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Am Heart J 2000, 139:S33-S37.

    Article  PubMed  CAS  Google Scholar 

  19. Phillips DR, Scarborough RM: Clinical pharmacology of eptifibitide. Am J Cardiol 1997, 80:11b-20b.

    Article  PubMed  CAS  Google Scholar 

  20. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996, 78(suppl 3A):35–40.

    Article  PubMed  CAS  Google Scholar 

  21. The PARAGON investigators. International, randomized, controlled trial of lamifiban (a glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97:2386–2395.

    Google Scholar 

  22. Kleiman NS, Califf RM: Results of late-breaking clinical trials at ACCIS 2000 and ACC 2000. J Am Coll Cardiol 2000, 36:310–325.

    Article  PubMed  CAS  Google Scholar 

  23. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998, 32:2003–2010.

    Article  Google Scholar 

  24. The OPUS investigators. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000, 102:149–156.

    Google Scholar 

  25. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes. Lancet 2000, 355:337–345.

    Article  Google Scholar 

  26. The EXCITE Investigators. Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000, 342:1316–1324.

    Article  Google Scholar 

  27. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330:956–961.

    Article  Google Scholar 

  28. Topol EJ, Califf RM, Weisman HF, et al.: Randomized trial of coronary intervention with antibody directed against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994, 343:881–886.

    Article  PubMed  CAS  Google Scholar 

  29. Topol EJ, Ferguson JJ, Weisman HF, et al.: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997, 278:479–484.

    Article  PubMed  CAS  Google Scholar 

  30. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689–1696.

    Article  Google Scholar 

  31. Lincoff AM, Tcheng JE, Califf RM, et al.: Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. Circulation 1999, 99:1951–1958.

    PubMed  CAS  Google Scholar 

  32. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997, 349:1429–1435.

    Article  Google Scholar 

  33. The IMPACT-II Investigators. Randomized, placebo-controlled trial of effect of eptifibitide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997, 349:1422–1428.

    Article  Google Scholar 

  34. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96:1445–1453.

    Google Scholar 

  35. Gibson CM, Goel M, Cohen DJ, et al.: Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol 1998, 32:28–34.

    Article  PubMed  CAS  Google Scholar 

  36. Phillips DR, Teng W, Arfsten A, et al.: Effect of Ca2+ on GP IIb/IIIa interactions with integrelin: enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997, 96:1488–1494.

    PubMed  CAS  Google Scholar 

  37. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998, 352:87–92.

    Article  Google Scholar 

  38. Lincoff AM, Califf RM, Moliterno DJ, et al.: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999, 341:319–327.

    Article  PubMed  CAS  Google Scholar 

  39. Topol EJ, Mark DB, Lincoff AM, et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre, randomized trial. Lancet 1999, 354:2019–2024.

    Article  PubMed  CAS  Google Scholar 

  40. ESPRIT Trial: Results from late-breaking clinical trials session at ACCIS 2000 and ACC 2000. American College of Cardiology. J Am Coll Cardiol 2000, 36:310–325.

    Article  Google Scholar 

  41. TARGET Trial: Randomized, Multicenter, Double-blind, abciximab-controlled study to evaluate the efficacy of tirofiban in patients undergoing percutaneous coronary intervention with intracoronary stent placement. Presented at the American Heart Association meeting, New Orleans, 2000.

  42. Brener SJ, Barr LA, Burchenal J, et al.: A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. The RAPPORT trial. Circulation 1998, 98:734–741.

    PubMed  CAS  Google Scholar 

  43. Schomig A, Kastrati A, Dirschinger J, et al.: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000, 343:385–391.

    Article  PubMed  CAS  Google Scholar 

  44. Hamm CW, Heeschen C, Goldmann B, et al.: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999, 340:1623–1629.

    Article  PubMed  CAS  Google Scholar 

  45. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibitide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436–443.

    Article  Google Scholar 

  46. The PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338:1498–1505.

    Article  Google Scholar 

  47. The PRISM-PLUS Investigators. Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 338:1488–1497.

    Article  Google Scholar 

  48. GUSTO IV-ACS: A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Reopro given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndromes without ST elevation. Presented at the European Society of Cardiology Meeting, Amsterdam, Holland, 2000.

  49. TACTICS: Treat angina with aggrastat and determine the cost of treatment with invasive or conservative strategy. Results presented at the American Heart Association meeting, New Orleans, 2000.

  50. HHThe GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615–1622.

    Article  Google Scholar 

  51. Kleiman NS, Ohman EM, Califf RM, et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: results of the TAMI-8 pilot study. J Am Coll Cardiol 1993, 22:381–389.

    Article  PubMed  CAS  Google Scholar 

  52. Antman EM, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999, 99:2720–2732.

    PubMed  CAS  Google Scholar 

  53. The SPEED Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for patency enhancement in the emergency department (SPEED) group. Circulation 2000, 101:2788–2794.

    Google Scholar 

  54. Holper EM, Giugliano RP, Antman EM: Glycoprotein IIb/IIIa inhibitors in acute ST segment elevation myocardial infarction. Coron Artery Dis 1999, 10:567–573.

    Article  PubMed  CAS  Google Scholar 

  55. Ohman EM, Kleiman NS, Gacioch G, et al.: Combined accelerated tissue plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with integrelin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997, 95:846–854.

    PubMed  CAS  Google Scholar 

  56. Tcheng JE, Kereiakes DJ, Braden GA, et al.: Readministration of abciximab: interim report of the ReoPro Readministration Registry. Am Heart J 1999, 138:S33–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Section, Baylor College of Medicine, 6550 Fannin, SM 677, 77030, Houston, TX, USA

    Phong Nguyen-Ho MD & Nasser M. Lakkis MD

Authors
  1. Phong Nguyen-Ho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nasser M. Lakkis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nguyen-Ho, P., Lakkis, N.M. Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease. Curr Atheroscler Rep 3, 139–148 (2001). https://doi.org/10.1007/s11883-001-0050-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-001-0050-7

Keywords

Search

Navigation